Has Diabetes Canada published a new single '2026' guideline document?

Diabetes Canada’s guidance in 2026 is delivered as an online suite of chapters and focused updates (e.g., kidney disease guidance, monitoring updates) rather than a single new book; the Quick Reference Guide summarises key targets and practical steps. See Diabetes Canada’s CPG portal for the latest chapters and updates.

What is the recommended A1C target in the 2026 guidance?

Typical targets for many non‑pregnant adults remain an A1C ≤7.0%, while tighter or looser targets are set based on age, comorbidity, hypoglycaemia risk and life expectancy. Diabetes Canada emphasises individualised targets and shared decision‑making.

Will my province pay for a continuous glucose monitor (CGM)?

Many provinces offer targeted programmes (e.g., Ontario ADP for rtCGM and insulin pumps) while others use PharmaCare or special authority mechanisms. Coverage varies—check your provincial ministry website or ask your diabetes educator for help with applications.

How often should I have my kidneys checked if I have diabetes?

Yes — Diabetes Canada recommends annual eGFR and urine albumin testing for people with diabetes, with more frequent monitoring when eGFR is <60 mL/min/1.73 m2 or urine albuminuria is present; early referral and use of kidney‑protective therapies are emphasised in the CKD update.

Should I be on an SGLT2 inhibitor or a GLP‑1 RA?

SGLT2 inhibitors and GLP‑1 receptor agonists are recommended earlier for people with established cardiovascular disease, heart failure or chronic kidney disease because of demonstrated cardiorenal benefits; medication choice should be individualised after discussing benefits and risks with your clinician.

Diabetes Canada Guidelines 2026: What You Need to Know

Q: Should I be on an SGLT2 inhibitor or a GLP‑1 RA?

SGLT2 inhibitors and GLP‑1 receptor agonists are recommended earlier for people with established cardiovascular disease, heart failure or chronic kidney disease because of demonstrated cardiorenal benefits; medication choice should be individualised after discussing benefits and risks with your clinician.

Author: Feras Alayed

Published: August 7, 2026

Updated: September 29, 2026

Category: diabetes

Reading Time: 10 minutes

📚 قراءات ذات صلة

(إدارة السكري)
السكر التراكمي (HbA1c): كيف تخفضه طبيعياً — الدليل العلمي الشامل 2026 (إدارة السكري)
أعراض السكري المبكرة: 15 علامة تحذيرية لا تتجاهلها (إدارة السكري)
كيف تحسّن مقاومة الأنسولين خلال 30 يوماً: خطة عملية مبنية على العلم (مقاومة الأنسولين)
كيف تعكس مقاومة الأنسولين في 90 يوماً (مقاومة الأنسولين)

مسارات مرتبطة داخل ATHAR

تعرّف على برنامج Feel Great
ابدأ من صفحة البداية المناسبة
الموقع الرسمي لـ Unicity